Phio Pharma (NASDAQ:PHIO) stock is pulling back on Thursday after the immuno-oncology therapeutics company’s shares underwent a major rally yesterday.
Investors will note that the company’s stock saw a 91.2% price increase during normal trading hours on Wednesday. That came alongside heavy trading, with more than 56 million shares changing hands. For the record, its daily average trading volume is closer to 908,000 shares.
You are viewing: Why Is Oncology Pharma Stock Falling
The news behind that rally was Phio Pharma reporting results from two preclinical studies. Both of these studies evaluated INTASYL compound PH-894. The studies showed the drug made melanoma cells more recognizable to immune cells while also confirming it acts as an antitumor cytotoxic agent.
PHIO Stock Movement on Thursday
Read more : Why No Dairy Before Colonoscopy
Following that massive rally yesterday, it makes sense that shares of PHIO stock would give up some of those gains today. However, it doesn’t look like the company will give up all of its gains, and it isn’t seeing heavy trading just yet.
PHIO stock is down 35% as of Thursday morning. To go along with that, some 300,000 shares of the company’s stock have changed hands already today. Even so, that’s still a far way off from its daily average trading volume.
Investors seeking out even more of the most recent stock market news are going to want to keep reading!
Read more : Why Does Ben Call Devi David
InvestorPlace is home to all of the hottest stock market news that traders need to know about on Thursday! That includes everything happening with shares of Tempest Therapeutics (NASDAQ:TPST) stock, Secoo (NASDAQ:SECO) stock and OpGen (NASDAQ:OPGN) stock today. You can catch up on all of this news by checking out the links below!
More Stock Market News for Thursday
- Why Is Tempest Therapeutics (TPST) Stock Down 35% Today?
- Why Is Secoo (SECO) Stock Up 703% Today?
- Why Is OpGen (OPGN) Stock Up 540% Today?
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Source: https://t-tees.com
Category: WHY
